Results 1 to 10 of about 38,609 (257)

Evaluation of Extended Interval Dosing Aminoglycosides in the Morbidly Obese Population [PDF]

Advances in Pharmacological Sciences, 2013
Aminoglycoside dosing has been studied in the obese population, typically recommending an adjusted weight utilizing a 40% dosing weight correction factor (IBW + 0.4 × (TBW–IBW)).
Ashley L. Ross, Jennifer L. Tharp, Gerald R. Hobbs, Richard McKnight, Aaron Cumpston   +4 more
doaj   +7 more sources

Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort [PDF]

Neurology and Therapy, 2023
Introduction Natalizumab, a therapy for relapsing–remitting multiple sclerosis (RRMS), is associated with a risk of progressive multifocal leukoencephalopathy (PML). Over the last several years, practitioners have used off-label extended interval dosing (
Juliette Pelle, Anais R. Briant, Pierre Branger, Nathalie Derache, Charlotte Arnaud, Christine Lebrun-Frenay, Mikael Cohen, Lydiane Mondot, Jerome De Seze, Kevin Bigaut, Nicolas Collongues, Laurent Kremer, Damien Ricard, Flavie Bompaire, Charlotte Ohlmann, Magali Sallansonnet-Froment, Jonathan Ciron, Damien Biotti, Beatrice Pignolet, Jean-Jacques Parienti, Gilles Defer   +20 more
doaj   +7 more sources

Extended-Interval Gentamicin Dosing for Pulmonic Tularemia [PDF]

Case Reports in Infectious Diseases, 2019
Francisella tularensis is a Gram-negative coccobacillus that is rarely encountered in clinical practice. Patients can present with cutaneous, pulmonary, cardiac, mucous membrane, or gastrointestinal involvement.
Tyson Dietrich, Katelynn Garcia, Joe Strain, John Ashurst   +3 more
doaj   +4 more sources

Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis [PDF]

Annals of Clinical and Translational Neurology
Objective We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti‐CD20 therapy on clinical and sub‐clinical outcomes in multiple sclerosis.
Nabil K. El Ayoubi, Fares Fahd, Hani Tamim, Salem Hannoun, Mark Bal, Elham El‐Hallak, Samia J. Khoury   +6 more
doaj   +3 more sources

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis [PDF]

Journal of Neuroinflammation, 2023
Background Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis (MS). However, it remains to be established whether certain B cell
Carla Rodriguez-Mogeda, Zoë Y. G. J. van Lierop, Susanne M. A. van der Pol, Loet Coenen, Laura Hogenboom, Alwin Kamermans, Ernesto Rodriguez, Jack van Horssen, Zoé L. E. van Kempen, Bernard M. J. Uitdehaag, Charlotte E. Teunissen, Maarten E. Witte, Joep Killestein, Helga E. de Vries   +13 more
doaj   +3 more sources

Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study. [PDF]

J Natl Cancer Inst, 2023
Abstract Background Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown.
Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Veccia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA, Aerts JGJV, Berardi R.   +50 more
europepmc   +11 more sources

Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study [PDF]

Frontiers in Immunology, 2021
The extended interval dosing (EID) of natalizumab has been suggested to be associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) and short-term preservation of efficacy but its long-term effectiveness remain unknown. We aimed
Javier Riancho, Javier Riancho, Javier Riancho, Javier Riancho, Sonia Setien, Jose Ramón Sánchez de la Torre, Marta Torres-Barquin, Mercedes Misiego, José Luis Pérez, Tamara Castillo-Triviño, Tamara Castillo-Triviño, Cristina Menéndez-García, Manuel Delgado-Alvarado, Manuel Delgado-Alvarado   +13 more
doaj   +4 more sources

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis [PDF]

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022
Background: Cognitive impairment and neuropsychiatric symptoms are frequently reported in Relapsing-Remitting Multiple Sclerosis (RRMS). Natalizumab (NTZ) is usually administered on a 4-weekly Standard Interval Dosing (SID) schedule.
Eileen J. McManus, Karen M. Clark, Christopher Frampton, Jamie A.B. Macniven, Jan Schepel   +4 more
doaj   +2 more sources

Pharmacodynamics of natalizumab extended interval dosing in MS. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2020
To determine if the concentration and saturation of natalizumab (NTZ) administration at extended interval dosing (EID; every 5-8 weeks) over 18 months is able to be maintained in the range considered adequate to sustain the clinical efficacy of NTZ.In a cross-sectional assessment of patients with multiple sclerosis (MS) who received standard interval ...
Zhovtis Ryerson L, Li X, Goldberg JD, Hoyt T, Christensen A, Metzger RR, Kister I, Foley J.   +7 more
europepmc   +4 more sources

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study [PDF]

Frontiers in Immunology, 2023
We aimed to assess the long-term safety and effectiveness of ocrelizumab in a cohort of patients with multiple sclerosis (MS) at high risk of progressive multifocal leukoencephalopathy (PML), previously treated with natalizumab in extending interval ...
Pilar Santiago-Setien, Cristina Barquín-Rego, Paula Hernández-Martínez, María Ezquerra-Marigomez, Marta Torres-Barquin, Cristina Menéndez-Garcia, Fernando Uriarte, Yésica Jiménez-López, Mercedes Misiego, Jose Ramón Sánchez de la Torre, Sonia Setien, Manuel Delgado-Alvarado, Manuel Delgado-Alvarado, Javier Riancho, Javier Riancho, Javier Riancho, Javier Riancho   +16 more
doaj   +2 more sources